JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

Search

Crinetics Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

40.12 -1.04

Résumé

Variation du prix de l'action

24h

Actuel

Min

39.79

Max

41.05

Chiffres clés

By Trading Economics

Revenu

-19M

-116M

Ventes

670K

1M

Marge bénéficiaire

-11,216.004

Employés

437

EBITDA

-19M

-129M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+99.36% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.4B

4B

Ouverture précédente

41.16

Clôture précédente

40.12

Sentiment de l'Actualité

By Acuity

50%

50%

168 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 oct. 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct. 2025, 22:13 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct. 2025, 21:20 UTC

Résultats

Correction to IBM 3Q Sales Jump Article

22 oct. 2025, 20:57 UTC

Résultats

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:15 UTC

Résultats

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct. 2025, 22:02 UTC

Résultats

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct. 2025, 21:59 UTC

Acquisitions, Fusions, Rachats

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct. 2025, 21:58 UTC

Acquisitions, Fusions, Rachats

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct. 2025, 21:57 UTC

Acquisitions, Fusions, Rachats

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct. 2025, 21:56 UTC

Acquisitions, Fusions, Rachats

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct. 2025, 21:47 UTC

Acquisitions, Fusions, Rachats

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct. 2025, 21:47 UTC

Résultats

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 21:47 UTC

Acquisitions, Fusions, Rachats

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct. 2025, 21:46 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct. 2025, 21:28 UTC

Market Talk
Résultats

Correction to Alcoa Tariff Market Talk

22 oct. 2025, 21:25 UTC

Résultats

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct. 2025, 21:17 UTC

Résultats

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct. 2025, 21:09 UTC

Market Talk
Résultats

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22 oct. 2025, 20:59 UTC

Résultats

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 20:51 UTC

Résultats

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 oct. 2025, 20:44 UTC

Résultats

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparaison

Variation de prix

Crinetics Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

99.36% hausse

Prévisions sur 12 Mois

Moyen 80.6 USD  99.36%

Haut 143 USD

Bas 40 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

15

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

30.39 / 33.46Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

168 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat